Standout Papers
Citation Impact
Citing Papers
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Evaluation of Common Variants in the Six Known Maturity-Onset Diabetes of the Young (MODY) Genes for Association With Type 2 Diabetes
2007
Risk of Diabetes in Offspring of Parents with Non‐insulin‐dependent Diabetes
1995
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
2004
Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes
2002
Pathogenesis of type 2 diabetes mellitus
2004
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes
1999
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
2006
Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians
2008
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
2010
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
2006
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
2000
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
2000 StandoutNature
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes
2005
Insulin resistance, insulin deficiency, and non-insulin-dependent diabetes mellitus
1991
Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: Where are the insulin resistance genes?
2008
Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland
1999
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
2006 StandoutNature
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes
2007
Genome scan for body mass index and height in the Framingham Heart Study
2003
Mammalian phosphoinositide kinases and phosphatases
2009 StandoutNobel
Lessons from the Cancer Genome
2013
The Human Obesity Gene Map: The 2005 Update
2006
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
2001
Candidate Gene Association Study in Type 2 Diabetes Indicates a Role for Genes Involved in β-Cell Function as Well as Insulin Action
2003
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
2004
Genetic and environmental determinants of non‐insulin‐dependent diabetes mellitus (NIDDM)
1992
Interleukin-1–Receptor Antagonist in Type 2 Diabetes Mellitus
2007
The biology of incretin hormones
2006 Standout
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
2004 Standout
Determinants of the Effectiveness of Glucagon-Like Peptide-1 in Type 2 Diabetes
2001
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
2002
Magnesium Replacement Improves the Metabolic Profile in Obese and Pre-Diabetic Patients with Mild-to-Moderate Chronic Kidney Disease: A 3-Month, Randomised, Double-Blind, Placebo-Controlled Study
2017 Standout
Molecular Defects in Insulin Secretion in Type-2 Diabetes
2004
IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice
2002 StandoutNature
Genes and type 2 diabetes mellitus
2008
The Type 2 Deiodinase A/G (Thr92Ala) Polymorphism Is Associated with Decreased Enzyme Velocity and Increased Insulin Resistance in Patients with Type 2 Diabetes Mellitus
2005
PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses
2007 Standout
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1
2004
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
2006
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019 Standout
Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men
2004
Candidate Genes for Type 2 Diabetes
2004
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
2005 StandoutNature
Type 2 diabetes
2017 Standout
Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' study
2011
Initial sequence of the chimpanzee genome and comparison with the human genome
2005 StandoutNature
Global and societal implications of the diabetes epidemic
2001 StandoutNature
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
2014
Genetic epidemiology of diabetes
2005
Mechanisms linking obesity to insulin resistance and type 2 diabetes
2006 StandoutNature
Insulin signalling and the regulation of glucose and lipid metabolism
2001 StandoutNature
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
2002
Intensified glucose control in type 2 diabetes—whose agenda?
2010
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
2009
GLP‐1 derivative liraglutide in rats with β‐cell deficiencies: influence of metabolic state on β‐cell mass dynamics
2003
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
2005
Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus
2000
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Insulin Sensitivity and Its Measurement: Structural Commonalities among the Methods1
2000
The Physiology of Glucagon-like Peptide 1
2007 Standout
Epigenetics and phenotypic variation in mammals
2006
The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death
2010 StandoutNatureNobel
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7)
2014
Common genetic variation near MC4R is associated with waist circumference and insulin resistance
2008
Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis
1994
Normalization of Glucose Concentrations and Deceleration of Gastric Emptying after Solid Meals during Intravenous Glucagon-Like Peptide 1 in Patients with Type 2 Diabetes
2003
Genetics of Type 2 diabetes
2005
Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
2001 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Genome-wide association studies for common diseases and complex traits
2005 Standout
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe
2006
The genetics of mammalian circadian order and disorder: implications for physiology and disease
2008
Islet cell failure in type 2 diabetes
2006
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
2010
Discovery and saturation analysis of cancer genes across 21 tumour types
2014 StandoutNature
Inflammation, metaflammation and immunometabolic disorders
2017 StandoutNature
Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study
2004
Incretins, insulin secretion and Type 2 diabetes mellitus
2004
The molecular neurobiology of depression
2008 StandoutNature
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Review of the Evidence on Fetal and Early Childhood Antecedents of Adult Chronic Disease
1996
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
2013 Standout
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
2010
Inflammasomes in health and disease
2012 StandoutNature
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
2004
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
2003
Parent-offspring trios: a resource to facilitate the identification of type 2 diabetes genes.
1999
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
The Inherited Basis of Diabetes Mellitus: Implications for the Genetic Analysis of Complex Traits
2003
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
2006
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Bioisosterism: A Rational Approach in Drug Design
1996
The Genetics of Type 2 Diabetes
2001
Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population
2007
Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes
2002
The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
2001
A Diabetes Outcome Progression Trial (ADOPT)
2002
Regulation of C. elegans Life-Span by Insulinlike Signaling in the Nervous System
2000 StandoutScienceNobel
No Evidence of Association of ENPP1 Variants With Type 2 Diabetes or Obesity in a Study of 8,089 U.K. Caucasians
2006
Carbohydrate Metabolism in Non-Insulin-Dependent Diabetes Mellitus
1992
Incretin hormones - an update
2001
Effects of Aging and a High Fat Diet on Body Weight and Glucose Tolerance in Glucagon-Like Peptide-1 Receptor−/− Mice*
1998
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
1984
Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes
2004
1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties
2003
Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration
2000
Functional mapping of disease susceptibility loci using cell biology
2006 StandoutNobel
Impaired insulin secretion and glucose intolerance in synaptotagmin-7 null mutant mice
2008 StandoutNobel
Differential Effects of Acute and Extended Infusions of Glucagon-Like Peptide-1 on First- and Second-Phase Insulin Secretion in Diabetic and Nondiabetic Humans
2003
A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gain
2010
Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects
2004
Dissociation betweenAPOC3variants, hepatic triglyceride content and insulin resistance
2010
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Genomics, Type 2 Diabetes, and Obesity
2010
A genetically clamped renin transgene for the induction of hypertension
2002 StandoutNobel
Is metabolic syndrome a discrete entity in the general population? Evidence from the Caerphilly and Speedwell population studies
1998
Regulation of apoptosis by the circadian clock through NF-κB signaling
2011 StandoutNobel
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
2011
Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments
2010 Standout
Glucagon-like Peptide 1 (GLP-1): An Intestinal Hormone, Signalling Nutritional Abundance, with an Unusual Therapeutic Potential
1999
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
2011
The Genetic Basis of Type 2 Diabetes Mellitus: Impaired Insulin Secretion versus Impaired Insulin Sensitivity
1998
A Genome-Wide Scan for Loci Linked to Plasma Levels of Glucose and HbA1c in a Community-Based Sample of Caucasian Pedigrees
2002
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
2014
ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGING
1995
Human Fatty Liver Disease: Old Questions and New Insights
2011 StandoutScience
Incretins and the development of type 2 diabetes
2006
The Glucagon-Like Peptides
1999
Reduced Insulinotropic Effect of Gastric Inhibitory Polypeptide in First-Degree Relatives of Patients With Type 2 Diabetes
2001
Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet
2011 StandoutNobel
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
2002
Adjust to Target in Type 2 Diabetes
2008
Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes
2005
Young Men With High-Normal Blood Pressure Have Lower Serum Adiponectin, Smaller LDL Size, and Higher Elevated Heart Rate Than Those With Optimal Blood Pressure
2002
The Metabolic Syndrome: Time for a Critical Appraisal
2005 Standout
Chemical Chaperones Reduce ER Stress and Restore Glucose Homeostasis in a Mouse Model of Type 2 Diabetes
2006 StandoutScience
Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region
2004
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
2000 StandoutScience
Response : Nitric Oxide and Arginine-Evoked Insulin Secretion
1992 StandoutScienceNobel
Works of J Lévy being referenced
Use and Abuse of HOMA Modeling
2004 Standout
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes
1999
PTEN Mutations as a Cause of Constitutive Insulin Sensitivity and Obesity
2012
Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in Type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study
1998
Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes‐related traits in UK samples
2005
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)
2005
Evidence for Linkage of Stature to Chromosome 3p26 in a Large U.K. Family Data Set Ascertained for Type 2 Diabetes
2002
GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77
2007
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
2007
Immunoradiometric assay of insulin, intact proinsulin and 32–33 split proinsulin and radioimmunoassay of insulin in diet-treated Type 2 (non-insulin-dependent) diabetic subjects
1992
Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
1997
No glucotoxicity after 53 hours of 6.0 mmol/l hyperglycaemia in normal man
1991
Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to Type 2 diabetes
2004
A Genetic Analysis of Type 2 (Non‐insulin‐dependent) Diabetes Mellitus in Punjabi Sikhs and British Caucasoid Patients
1987
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
2009
Hyperglycaemic Progression in Subjects with Impaired Glucose Tolerance: Association with Decline in Beta Cell Function
1993
Segregation analysis of NIDDM in Caucasian families
1994
Analysis of the contribution to type 2 diabetes susceptibility of sequence variation in the gene encoding stearoyl-CoA desaturase, a key regulator of lipid and carbohydrate metabolism
2004
An increase in insulin sensitivity and basal beta‐cell function in diabetic subjects treated with pioglitazone in a placebo‐controlled randomized study
2004
Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects.
1993
Changes in Amylin and Amylin-Like Peptide Concentrations ana (β-Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM
1998
3 Pathogenesis of NIDDM—a disease of deficient insulin secretion
1988
Evidence From a Large U.K. Family Collection That Genes Influencing Age of Onset of Type 2 Diabetes Map to Chromosome 12p and to the MODY3/NIDDM2 Locus on 12q24
2004
Time-dependent inhibition of insulin release: suppression of the arginine effect by hyperglycaemia
1984
Meta-Analysis and a Large Association Study Confirm a Role for Calpain-10 Variation in Type 2 Diabetes Susceptibility
2003
Availability of Type II Diabetic Families for Detection of Diabetes Susceptibility Genes
1993
Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is associated with susceptibility to hypertension and type 2 diabetes
2007
Understanding “insulin resistance”: Both glucose resistance and insulin resistance are required to model human diabetes
1991
Distribution of Type II Diabetes in Nuclear Families
1993
Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes.
1999
Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III variable number tandem repeat alleles.
2000
Type II Diabetes: Clinical Aspects of Molecular Biological Studies
1995
Significant Linkage of BMI to Chromosome 10p in the U.K. Population and Evaluation of GAD2 as a Positional Candidate
2006
Clinical Usefulness of Cystatin C for the Estimation of Glomerular Filtration Rate in Type 1 Diabetes
2002
Polymorphisms in Type II SH2 Domain–Containing Inositol 5-Phosphatase (INPPL1, SHIP2) Are Associated With Physiological Abnormalities of the Metabolic Syndrome
2004
Large-Scale Association Studies of Variants in Genes Encoding the Pancreatic β-Cell KATP Channel Subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) Confirm That the KCNJ11 E23K Variant Is Associated With Type 2 Diabetes
2003
Erectile Dysfunction in Diabetes Mellitus
2009
Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM
1996
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance.
1993